1. Rothman DL, Shulman RG, Shulman GI. 31-P nuclear magnetic resonance measurements of muscle glucose-6-phosphate. J Clin Invest 1992;89:1069–1075.
2. Butler PC, Kryshak EJ, Marsh M, et al. Effect of insulin on oxidation of intracellularly and extracellularly derived glucose in patients with NIDDM—evidence for primary defect in glucose transport and/or phosphorylation but not oxidation. Diabetes 1990;39:1373–1380.
3. Yki-Jarvinen H, Sahlin K, Ren JM, et al. Localization of rate limiting defect for glucose disposal in skeletal muscle of insulin resistant type 1 diabetic patients. Diabetes 1990;39:157–167.
4. Garvey WT, Maianu L, Huecksteadt TP, et al. Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin dependent diabetes mellitus and obesity. J Clin Invest 1991;87:1072–1081.
5. Zierath JR, Galuska D, Nolte LA, et al. Effects of glycaemia on glucose transport in isolated skeletal muscle from patients with NIDDM: in vitro reversal of muscular insulin resistance. Diabetologia 1994;37:270–277.
6. Dohm GL, Tapscott EB, Pories WJ, et al. An in vitro human muscle preparation suitable for metabolic studies: decreased insulin stimulation of glucose transport in muscle from morbidly obese diabetic subjects. J Clin Invest 1988;82:486–494.
7. Friedman JE, Dohm GL, Leggett-Frazier N, et al. Restoration of insulin responsiveness in skeletal muscle of morbidly obese patients after weight loss: effect on muscle glucose transport and glucose transporter GLUT4. J Clin Invest 1992;89:701–705.
8. Fink RI, Wallace P, Brechtel G, et al. Evidence that glucose transport is rate limiting for in vivo glucose uptake. Metabolism 1992;41:897–902.
9. Katz A, Nyomba BL, Bogardus C. No accumulation of glucose in human skeletal muscle during euglycemic hyperinsulinemia. Am J Physiol 1988;255:E942–E945.
10. Yki-Jarvinen H, Helve E, Koivisto VA. Hyperglycemia decreases glucose uptake in type 1 diabetes. Diabetes 1987;36:892–896.
11. Joost HG, Bell GI, Best JD, et al. Nomenclature of the GLUT/ SLC2A family of sugar/polyol transport facilitators. Am J Physiol Endocrinol Metab 2002;282:E974–E976.
12. Abel ED, Peroni OD, Kim JK, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 2001;409:729–733.
13. Rea S, James DE. Moving GLUT4: the biogenesis and trafficking of GLUT4 storage vesicles. Diabetes 1997;46:1667–1677.
14. Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J 1998;333: 471–490.
15. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001;414:799–806.
16. Mastick CC, Aebersold R, Lienhard GE. Characterisation of a major protein in GLUT4 vesicles. J Biol Chem 1994;269:6089–6092.
17. Kandror K, Pilch P. gp160, a tissue specific marker for insulin activated glucose transport. Proc Natl Acad Sci USA 1994;91:8017–8021.
18. Kupriyanova TA, Kandror V, Kandror KV. Isolation and characterization of the two major intracellular Glut4 storage compartments. J Biol Chem 2002;277:9133–9138.
19. Kupriyanova TA, Kandror KV. Cellugyrin is a marker for a distinct population of intracellular Glut4-containing vesicles. J Biol Chem 2000;275:36263–36268.
20. Maianu L, Keller SR, Garvey WT. Adipocytes exhibit abnormal subcellular distribution and translocation of vesicles containing glucose transporter 4 and insulin-regulated aminopeptidase in type 2 diabetes mellitus: implications regarding defects in vesicle trafficking. J Clin Endocrinol Metab 2001;86:5450–5456.
21. Garvey WT, Maianu L, Zhu JH, et al. Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. J Clin Invest 1998;101:2377–2386.
22. Shepherd PR, Kahn BB. Glucose transporters and insulin action: implications for insulin resistance and diabetes mellitus. N Engl J Med 1999;341:248–257.
23. Cormont M, Bortoluzzi M, Gautier N, et al. Potential role of Rab4 in the regulation of subcellular localization of GLUT4 in adipocytes. Mol Cell Biol 1996;16:6879–6886.
24. Clark AE, Holman GD, Kozka IJ. Determination of the rates of appearance and loss of glucose transporters at the cell surface of rat adipose cells. Biochem J 1991;278:235–241.
25. Vannucci SJ, Nishimura H, Simpson IA. Cell surface accessibility of GLUT4 glucose transporters in rat adipose cells: effects of isoproterenol and adenosine. Biochem J 1992;288:325–330.
26. Han XX, Bonen A. Epinephrine translocates GLUT-4 but inhibits insulin-stimulated glucose transport in rat muscle. Am J Physiol 1998;274:E700–E707.
27. Kahn BB. Facilitative glucose transporters: regulatory mechanisms and disregulation in diabetes. J Clin Invest 1992;89:1367–1374.
28. Clancy BM, Harrison SA, Buxton JM, et al. Protein synthesis inhibitors activate glucose transport without increasing plasma membrane glucose transporters in 3T3-L1 adipocytes. J Biol Chem 1991;266:10122–10130.
29. Okumura N, Shimazu T. Vanadate stimulates D-glucose transport into sarcolemmal vesicles from rat skeletal muscles. J Biochem 1992; 112:107–111.
30. Somwar R, Kim DY, Sweeney G, et al. GLUT4 translocation precedes the stimulation of glucose uptake by insulin in muscle cells: potential activation of GLUT4 via p38 mitogen-activated protein kinase. Biochem J 2001;359:639–649.
31. Konrad D, Bilan PJ, Nawaz Z, et al. Need for GLUT4 activation to reach maximum effect of insulin-mediated glucose uptake in brown adipocytes isolated from GLUT4myc-expressing mice. Diabetes 2002;51:2719–2726.
32. Jhun BH, Rampal AL, Liu H, et al. Effects of insulin on steady state kinetics of GLUT4 subcellular distribution in rat adipocytes. J Biol Chem 1992;267:17710–17715.
33. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 1997;5:177–269.
34. Koranyi LI, Bourey RE, Vuorinen-Markkola H, et al. Level of skeletal muscle glucose transporter protein correlates with insulin stimulated whole body glucose disposal in man. Diabetologia 1991;34: 763–765.
35. Seidner G, Alvarez MG, Yeh JI, et al. GLUT1 deficiency syndrome caused by haploinsufficiency of the blood brain barrier hexose carrier. Nat Genet 1998;18:188–191.
36. Santer R, Schneppenheim R, Dombrowski A, et al. Mutations in GLUT2, the gene for liver type glucose transporter, in patients with Fanconi-Bickel syndrome. Nat Genet 1997;17:324–326.
37. O’Rahilly S, Rook A, Morgan R, et al. Insulin receptor and insulin responsive glucose transporter (GLUT4) mutations and polymorphisms in a Welsh type 2 (non insulin dependent) diabetic population. Diabetologia 1992;35:486–489.
38. Kusari J, Verma US, Buse JB, et al. Analysis of the gene sequences of the insulin receptor and insulin sensitive glucose transporter (GLUT4) in patients with common type non insulin dependent diabetes mellitus. J Clin Invest 1991;88:1323–1330.
39. Choi WH, O’Rahilly S, Buse JB, et al. Molecular scanning of insulin responsive glucose transporter (GLUT4) gene in NIDDM subjects. Diabetes 1991;40:1712–1718.
40. Bjørbæk C, Eckwald SM, Hubricht P, et al. Genetic variation in the promoter and coding regions of the muscle glycogen synthase and the insulin responsive GLUT4 genes in NIDDM. Diabetes 1994; 43:976–983.
41. Baroni MG, Alcolado JC, Gragnoli C, et al. Affected sib-pair analysis of the GLUT-1 glucose transporter gene locus in NIDDM—evidence for no linkage. Hum Genet 1994;93:675–680.
42. Pontiroli AE, Capra F, Veglia F, et al. Genetic contribution of polymorphism of the GLUT1 and GLUT4 genes to the susceptibility to type 2 (non–insulin-dependent) diabetes mellitus in different populations. Acta Diabetol 1996;33:193–197.
43. Olson AL, Pessin JE. Transcriptional regulation of GLUT4 gene expression. Semin Cell Dev Biol 1996;7:287–293.
44. Zheng D, MacLean PS, Pohnert SC, et al. Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase. J Appl Physiol 2001;91:1073–1083.
45. MacLean PS, Zheng D, Dohm GL. Muscle glucose transporter (GLUT 4) gene expression during exercise. Exerc Sport Sci Rev 2000; 28:148–152.
46. Oshel KM, Knight JB, Cao KT, et al. Identification of a 30-base pair regulatory element and novel DNA binding protein that regulates the human GLUT4 promoter in transgenic mice. J Biol Chem 2000; 275:23666–23673.
47. Pedersen O, Bak JF, Andersen PH, et al. Evidence against altered expression of GLUT1 or GLUT4 in skeletal muscle of patients with obesity or NIDDM. Diabetes 1990;39:865–870.
48. Garvey WT, Maianu L, Hancock JA, et al. Gene expression of GLUT4 in skeletal muscle from insulin resistant patients with obesity, IGT, GDM and NIDDM. Diabetes 1992;41:465–475.
49. Kahn BB, Rosen AS, Bak JF, et al. Expression of GLUT1 and GLUT4 glucose transporters in skeletal muscle of humans with insulin dependent diabetes mellitus: regulatory effects of metabolic factors. J Clin Endocrinol Metab 1992;74:1101–1109.
50. Koivisto U, Martinez-Valdez H, Bilan PJ, et al. Differential regulation of the GLUT1 and GLUT4 glucose transport systems by insulin and glucose in L6 muscle cells in culture. J Biol Chem 1991; 266:2615–2621.
51. Vogt B, Muhlbacher C, Carrascosa J, et al. Subcellular distribution of GLUT4 in skeletal muscle of lean type 2 (non–insulin dependent) diabetic patients in the basal state. Diabetologia 1992;35:456–463.
52. Dohm GL, Elton CW, Friedman JE, et al. Decreased expression of glucose transporter in muscle of insulin resistant patients. Am J Physiol 1991;260:E459–E463.
53. Friedman JE, Dohm GL, Elton CW, et al. Muscle insulin resistance in uremic humans: glucose transport, glucose transporters and insulin receptors. Am J Metab 1991;261:E87–E94.
54. Flier J, Moller D, Moses A, et al. Insulin mediated pseudoacromegaly: clinical and biochemical characterization of a syndrome of selective insulin resistance. J Clin Endocrinol Metab 1993;76: 1533–1541.
55. Vestergaard H, Weinreb JE, Rosen AS. Sulphonylurea therapy improves glucose disposal without changing skeltal muscle GLUT4 levels in NIDDM. J Clin Endocrinol Metab 1995;80:270–275.
56. Yki-Jarvinen H, Vuorinen-Markkola H, Koranyi L, et al. Defect in insulin action on expression of the muscle/adipose tissue specific glucose transporter gene in skeletal muscle of type 1 diabetics. J Clin Endocrinol Metab 1992;75:795–799.
57. Andersen P, Lund S, Vestergaard H. Expression of the major insulin regulatable glucose transporter (GLUT4) in skeletal muscle of NIDDM patients and healthy subjects before and after insulin infusion. J Clin Endocrinol Metab 1993;77:27–32.
58. Elahi D, McAloon-Dyke M, Clark B, et al. Sequential evaluation of islet cell responses to glucose in the transplanted pancreas in humans. Am J Surg 1993;165:15–22.
59. Zierath JR, He L, Guma A, et al. Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM. Diabetologia 1996;39:1180–1189.
60. Goodyear LJ, Hirshman MF, Napoli R, et al. Glucose ingestion causes GLUT4 translocation in human skeletal muscle. Diabetes 1996;45:1051–1056.
61. Kennedy JW, Hirshman MF, Gervino EV, et al. Acute exercise induces GLUT4 translocation in skeletal muscle of normal human subjects with type2 diabetes. Diabetes 1999;48:1192–1197.
62. Ryder JW, Yang J, Galuska D, et al. Use of a novel impermeable biotinylated photolabeling reagent to assess insulin- and hypoxia-stimulated cell surface GLUT4 content in skeletal muscle from type 2 diabetic patients. Diabetes 2000;49:647–654.
63. Hayashi T, Hirshman MF, Kurth EJ, et al. Evidence for 5′AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes 1998;47:1369–1373.
64. Rosenbaum D, Haber RS, Dunaif A. Insulin resistance in polycystic ovary syndrome—decreased expression of the GLUT-4 glucose transporter. Am J Physiol 1993;264:E197–E202.
65. Garvey WT, Maianu L, Zhu JH, et al. Multiple defects in adipocyte glucose transport system cause cellular insulin resistance in gestational diabetes: heterogeneity in the number and a novel defect in subcellular distribution of the insulin responsive GLUT4 isoform. Diabetes 1993;42:1773–1785.
66. Marin P, Rebuffe-Scive M, Smith U, et al. Glucose uptake in human adipose tissue. Metabolism 1987;36:1154–1160.
67. Kim Y, Uotani S, Pierroz D, et al. In vivo administration of leptin activates signal transduction directly in insulin sensitive tissues; overlapping but distinct pathways from insulin. Endocrinology 2000;141: 2328–2339.
68. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002; 415:339–343.
69. Hotamisligil GS, Spiegelman BM. Tumour necrosis factor alpha—a key component of the obesity diabetes link. Diabetes 1994;43:1271–1278.
70. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307–312.
71. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002;13:84–89.
72. Houmard JA, Egan PC, Neufer PD, et al. Elevated skeletal muscle glucose transporter levels in exercise trained middle aged men. Am J Physiol 1991;261:E437–E443.
73. Hughes VA, Fiatarone MA, Fielding RA, et al. Effects of aerobic exercise on glucose homeostasis and GLUT4 levels in muscle of older subjects with impaired glucose tolerance. Am J Physiol 1993;264: E855–E862.
74. Dela F, Ploug T, Handberg A, et al. Physical training increase muscle GLUT4 protein and mRNA in patients with NIDDM. Diabetes 1994;43:862–865.
75. Houmard JA, Shinebarger M. Exercise training increase GLUT4 protein content in sedentary middle aged men. Am J Physiol 1993; 264:E896–E901.
76. Andersen P, Lund S, Vestergaard H, et al. Increased insulin stimulated glucose uptake in athletes: the importance of GLUT4 mRNA, GLUT4 protein and fibre type composition of skeletal muscle. Acta Physiol Scand 1993;149:393–404.
77. Zarjevski N, Doyle P, Jeanrenaud B. Muscle insulin resistance may not be a primary etiological factor in genetically obese fa/fa rat. Endocrinology 1992;130:1564–1570.
78. Penicaud L, Ferre P, Terrettaz J, et al. Development of obesity in Zucker rats: early insulin resistance in muscle but normal sensitivity in white adipose tissue. Diabetes 1987;36:626–631.
79. Pedersen O, Kahn CR, Kahn BB. Divergent regulation of the GLUT1 and GLUT4 glucose transporters in isolated adipocytes from Zucker rats. J Clin Invest 1992;89:1964–1973.
80. Kahn BB, Pedersen O. Suppression of GLUT4 expression in skeletal muscle of rats which are obese from high fat feeding but not from high carbohydrate feeding or genetic obesity. Endocrinology 1993; 132:13–22.
81. Brichard SM, Assimacopoulos-Jeannet F, Jeanrenaud B. Vanadate treatment markedly increases glucose utilization in muscle of insulin resistant fa/fa rats without modifying glucose transporter expression. Endocrinology 1992;131:311–317.
82. Brozinick JT, Etgen GJ, Yaspelkis BB, et al. Glucose uptake and GLUT4 distribution in skeletal muscle of obese Zucker rats. Am J Physiol 1994;267:R236-R243.
83. King PA, Horton ED, Hirshman MF, et al. Insulin resistance in obese Zucker rat (fa/fa) skeletal muscle is associated with a failure of glucose transporter translocation. J Clin Invest 1992;90:1568–1575.
84. Carvalho E, Rondinone C, Smith U. Insulin resistance in fat cells from obese Zucker rats—evidence for an impaired activation and translocation of protein kinase B and glucose transporter 4. Mol Cell Biochem 2000;206:7–16.
85. Kim YB, Peroni OD, Franke TF, et al. Divergent regulation of Akt1 and Akt2 isoforms in insulin target tissues of obese Zucker rats. Diabetes 2000;49:847–856.
86. Betts J, Valyou PM, Hirshman MF, et al. Adrenalectomy and glucose metabolism in the obese (fa/fa) Zucker rat. Diabetes 1991;41(suppl): 152A.
87. Stubbs M, York DA. Central glucocorticoid regulation of parasympathetic drive to pancreatic β-cells in obese fa/fa rats. Int J Obes 1991;15:547–553.
88. Slieker LJ, Sundell KL, Heath WF, et al. Glucose transporter levels in tissues of spontaneously diabetic Zucker fa/fa rat (ZDF/drt) and viable yellow mouse (Avy/a). Diabetes 1992;41:187–193.
89. Friedman JE, Vente JED, Peterson RG, et al. Altered expression of muscle glucose transporter GLUT4 in diabetic fatty Zucker rats (ZDF/Drt-fa). Am J Physiol 1991;261:E782–E788.
90. Yamamoto T, Fukumoto H, Koh G, et al. Liver and muscle fat type glucose transporter gene expression in obese and diabetic rats. Biochem Biophys Res Commun 1991;175:995–1002.
91. Chan TM, Tatoyan A. Glucose transport in the perfused hindquarters of lean and obese hyperglycemic (db/db) mice: effect of insulin and electrical stimulation. Biochim Biophys Acta 1984;798:325–332.
92. Koranyi L, James DE, Mueckler M, et al. Glucose transporter levels in spontaneously obese (db/db) insulin resistant mice. J Clin Invest 1990;85:962–967.
93. Brozinick JT Jr, McCoid SC, Reynolds TH, et al. GLUT4 overexpression in db/db mice dose-dependently ameliorates diabetes but is not a lifelong cure. Diabetes 2001;50:593–600.
94. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425–432.
95. Grundleger ML, Godbole VY, Thenen SW. Age related development of insulin resistance of soleus muscle in genetically obese (ob/ob) mice. Am J Physiol 1980;239:E363–E371.
96. Song XM, Fiedler M, Galuska D, et al. 5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia 2002;45:56–65.
97. McGinnis R, Walker J, Margules D. Genetically obese (ob/ob) mice are hypersensitive to glucocorticoid stimulation of feeding but dramatically resist glucocorticoid induced weight loss. Life Sci 1987;40: 1561–1570.
98. Ohshima K, Shargill NS, Chan TM, et al. Adrenalectomy reverses insulin resistance in muscle from obese (ob/ob) mice. Am J Physiol 1984;246:E193–E197.
99. Brichard SM, Bailey CJ, Henquin JC. Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate. Diabetes 1990;39:1326–1332.
100. Lachaal M, Jung CY. Insulin resistance in hypertension. Mol Cell Biochem 1992;109:119–125.
101. Reaven GM, Chang H, Hoffman BB, et al. Resistance to insulin stimulated glucose uptake in adipocytes isolated from spontaneously hypertensive rats. Diabetes 1989;38:1155–1160.
102. Frontoni S, Ohman L, Haywood JR, et al. In vivo insulin action in genetic models of hypertension. Am J Physiol 1992;262:E191–E196.
103. Mondon CE, Reaven GM. Evidence of abnormalities of insulin metabolism in rats with spontaneous hypertension. Metabolism 1988; 37:303–305.
104. Bader S, Scholz R, Kellerer M, et al. Normal insulin receptor tyrosine kinase activity and glucose transporter (GLUT4) levels in skeletal muscle of hyperinsulinaemic hypertensive rats. Diabetologia 1992;35:712–718.
105. James DJ, Cairns F, Salt IP, et al. Skeletal muscle of stroke-prone spontaneously hypertensive rats exhibits reduced insulin-stimulated glucose transport and elevated levels of caveolin and flotillin. Diabetes 2001;50:2148–2156.
106. Campbell IW, Dominiczak AF, Livingstone C, et al. Analysis of the glucose transporter compliment of metabolically important tissues from the Milan hypertensive. Biochem Biophys Res Commun 1995; 211:780–791.
107. Lowell BB, Susulic V, Hamann A, et al. Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature 1993;366:740–742.
108. Hamann A, Benecke H, LeMarchand-Brustel Y, et al. Characterisation of insulin resistance and NIDDM in transgenic mice with reduced brown fat. Diabetes 1995;44:1266–1273.
109. Furuta M, Yano Y, Gabazza EC, et al. Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus. Diabetes Res Clin Pract 2002;56:159–171.
110. Kanoh Y, Bandyopadhyay G, Sajan MP, et al. Rosiglitazone, insulin treatment, and fasting correct defective activation of protein kinase C-zeta/lambda by insulin in vastus lateralis muscles and adipocytes of diabetic rats. Endocrinology 2001;142:1595–1605.
111. Krook A, Kawano Y, Song XM, et al. Improved glucose tolerance restores insulin-stimulated Akt kinase activity and glucose transport in skeletal muscle from diabetic Goto-Kakizaki rats. Diabetes 1997;46: 2110–2114.
112. Miura T, Suzuki W, Ishihara E, et al. Impairment of insulin-stimulated GLUT4 translocation in skeletal muscle and adipose tissue in the Tsumura Suzuki obese diabetic mouse: a new genetic animal model of type 2 diabetes. Eur J Endocrinol 2001;145:785–790.
113. Hofmann C, Lorenz K, Colca JR. Glucose transporter deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology 1991;129:1915–1925.
114. Marette A, Atgie C, Liu Z, et al. Differential regulation of GLUT1 and GLUT4 glucose transporters in skeletal muscle of a new model of type II diabetes: the obese SHR/N-cp rat. Diabetes 1993;42: 1195–2001.
115. Kern M, Mondon C, Butte J, et al. GLUT4 content and insulin receptor kinase activity in muscles of LA/N-cp rat. Horm Metab Res 1994;26:129–132.
116. Cousin B, Agou K, Leturque A, et al. Molecular and metabolic changes in white adipose tissue of the rat during development of ventromedial hypothalamic obesity. Eur J Biochem 1992;207:377–382.
117. Marchand-Brustel YL, Olichon-Berthe C, Gremeaux T, et al. Glucose transporter in insulin sensitive tissues of lean and obese mice: effect of thermogenic agent BRL 26830A. Endocrinology 1990;127: 2687–2695.
118. Zarjevski N, Cusin I, Vettor R, et al. Intracerebroventricular administration of neuropeptide Y to normal rats has divergent effects on glucose utilization by adipose tissue and skeletal muscle. Diabetes 1994;43:764–769.
119. Machado U, Shimizu Y, Saito M. Decreased GLUT4 content in insulin sensitive tissues of orthotioglucose and monosodium glutamate treated mice. Horm Metab Res 1993;25:462–465.
120. Machado U, Shimizu Y, Saito M. Reduced content and preserved translocation of GLUT4 in white adipose tissue of obese mice. Physiol Behav 1994;55:621–625.
121. Kraegen EW, James DE, Starlien LH, et al. In vivo insulin resistance in individual peripheral tissues of the high fat fed rat: assessment by euglycemic clamp plus deoxyglucose administration. Diabetologia 1986;29:192–198.
122. Starlien LH, Jenkins AB, Chisholm DJ, et al. Influence of dietary fat composition on development of insulin resistance in rats: relationship to muscle triglyceride and w3 fatty acids in muscle phospholipid. Diabetes 1991;40:280–289.
123. Pedersen O, Kahn CR, Flier JS, et al. High fat feeding causes insulin resistance and a marked decrease in the expression of glucose transporters (GLUT4) in fat cells of rats. Endocrinology 1991;129:771–777.
124. Rosholt M, King P, Horton E. High fat diet reduces glucose transporter responses to both insulin and exercise. Am J Physiol 1994;266: R95–R101.
125. Murer E, Boden G, Gyda M, et al. Effects of oleate and insulin on glucose uptake, oxidation and glucose transporter proteins in rat adipocytes. Diabetes 1992;41:1063–1068.
126. Zierath JR, Housenecht KL, Gnudi L, et al. High-fat feeding impairs insulin-stimulated GLUT4 recruitment via an early insulin-signaling defect. Diabetes 1997;46:215–223.
127. Tremblay F, Lavigne C, Jacques H, et al. Defective insulin-induced GLUT4 translocation in skeletal muscle of high fat-fed rats is associated with alterations in both Akt/protein kinase B and atypical protein kinase C (zeta/lambda) activities. Diabetes 2001;50:1901–1910.
128. Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1 associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999;103:253–259.
129. Kim JK, Fillmore JJ, et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci USA 2001;98:7522–7527.
130. Griffin ME, Marcucci MJ, Cline GW, et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 1999;48:1270–1274.
131. Yu C, Chen Y, Zong H, et al. Mechanism by which fatty acids inhibit insulin activation of IRS-1 associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002;277:50230–50236.
132. Kim YB, Shulman GI, Kahn BB. Fatty acid infusion selectively impairs insulin action on Akt1 and protein kinase C lambda/zeta but not on glycogen synthase kinase-3. J Biol Chem 2002;277:32915–32922.
133. Cusin I, Terrettaz J, Rohner-Jeanrenaud F, et al. Metabolic consequences of hyperinsulinemia imposed on normal rats on glucose handling by white adipose tissue, muscles and liver. Biochem J 1990; 267:99–103.
134. Kahn BB, Cushman SW. Mechanism for markedly hyperresponsive insulin stimulated glucose transport activity in adipose cells from insulin treated streptozotocin diabetic rats. J Biol Chem 1987;262: 5118–5124.
135. Laville M, Auboeuf D, Khalfallah Y, et al. Acute regulation by insulin of phosphatidylinositol-3-kinase, Rad, Glut 4, and lipoprotein lipase mRNA levels in human muscle. J Clin Invest 1996;98:43–49.
136. Balage M, Larbaud D, Debras E, et al. Acute hyperinsulinemia fails to change GLUT-4 content in crude membranes from goat skeletal muscles and adipose tissue. Comp Biochem Physiol A Mol Integr Physiol 1998;120:425–430.
137. Flores-Riveros J, McLenithan J, Ezaki O, et al. Insulin downregulates expression of the insulin responsive glucose transporter gene: effects on transcription and mRNA turnover. Proc Natl Acad Sci USA 1993;90:512–516.
138. Bourey RE, Koranyi L, James DE, et al. Effects of altered glucose homeostasis on glucose transporter expression in skeletal muscle of rat. J Clin Invest 1990;86:542–547.
139. Cusin I, Terrettaz J, Rohner-Jeanrenaud F, et al. Hyperinsulinemia increases the amount of GLUT4 mRNA in white adipose tissue and decreases it in muscle: a clue for increased fat depot and insulin resistance. Endocrinology 1990;127:3246–3248.
140. Hager SR, Pastorek D, Jochen AL, et al. Divergence between GLUT4 mRNA and protein abundance in skeletal muscle of insulin resistant rat. Biochem Biophys Res Commun 1991;181:240–245.
141. Haber RS, Weinstein SP. Role of glucose transporters in glucocorticoid-induced insulin resistance: GLUT4 nor decreased in rat skeletal muscle is not decreased by dexamethasone. Diabetes 1992;41:728–735.
142. Giorgino F, Almahfouz A, Goodyear LJ, et al. Glucocorticoid regulation of the insulin receptor and substrate (IRS-1) tyrosine phosphorylation in rat skeletal muscle in vivo. J Clin Invest 1993;91:2020–2030.
143. Carter-Su C, Okamoto K. Effect of insulin and glucocorticoids on glucose transport in rat adipocytes. Am J Physiol 1987;252:E441–E443.
144. McGrane MM, Yun JS, Moorman AF, et al. Metabolic effects of developmental, tissue, and cell specific expression of chimeric phosphoenolpyruvate carboxykinase (GTP)/bovine growth hormone gene in transgenic mice. J Biol Chem 1990;265:22371–22379.
145. Tai PK, Liao JF, Chen EH, et al. Differential regulation of two glucose transporters by chronic growth hormone treatment of culture 3T3-F442A adipose cells. J Biol Chem 1990;265:21828–21834.
146. Oka Y, Asano T, Lin J, et al. Expression of glucose transporter isoforms with ageing. Gerontology 1992;38:3–9.
147. Schoenle E, Zapf J, Froesch ER. Regulation of rat adipocyte glucose transport by growth hormone: no mediation by insulin-like growth factors. Endocrinology 1983;112:384–386.
148. Houmard JA, Weidner MD, Dolan PL, et al. Skeletal muscle GLUT4 protein concentration and aging in humans. Diabetes 1995;44:555–560.
149. Cartee G. Myocardial GLUT4 glucose transporter protein levels decline with advancing age. J Gerontol 1993;48:B168–B170.
150. Gulve E, Henrikson E, Rodnick K, et al. Glucose transporters and glucose transport in skeletal muscle of rats aged 1 to 25 months. Am J Physiol 1993;264:E319–E327.
151. Ezaki O, Fukuda N, Itakura H. Role of two types of glucose transporters in enlarged adipocytes from aged and obese rats. Diabetes 1990;39:1543–1549.
152. Matthaei S, Benecke H, Klein HH, et al. Potential mechanism of insulin resistance in ageing: impaired insulin stimulated glucose transport due to a depletion of the intracellular pool of glucose transporters in Fischer rat adipocytes. J Endocrinol 1990;126:99–107.
153. Kahn BB, Shulman GI, DeFronzo RA, et al. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest 1991;87:561–570.
154. Kahn BB, Rossetti L, Lodish HF, et al. Decreased in vivo glucose uptake but normal expression of GLUT1 and GLUT4 in skeletal muscle of diabetic mice. J Clin Invest 1991;87:2197–2206.
155. Youn J, Kim J, Buchanan T. Time courses of changes in hepatic and skeletal muscle insulin action and GLUT4 protein in skeletal muscle after STZ injection. Diabetes 1994;43:564–571.
156. Sivitz W, DeSautel SL, Lee EC, et al. Time dependent regulation of rat adipose tissue glucose transporter (GLUT4) mRNA and protein by insulin in streptozocin diabetic and normal rats. Metabolism 1992;41:1267–1272.
157. Camps M, Castello A, Munoz P, et al. Effect of diabetes and fasting on GLUT4 (muscle/fat) glucose transporter expression in insulin sensitive tissues: heterogenous response in heart, red and white muscle. Biochem J 1992;282:765–772.
158. Kainulainen H, Breiner M, Schurmann A, et al. In vivo glucose uptake and glucose transporter proteins GLUT1 and GLUT4 in heart and various types of skeletal muscle from streptozotocin diabetic rats. Biochim Biophys Acta 1994;1225:275–282.
159. Neufer P, Carey J, Dohm G. Transcriptional regulation of the gene for GLUT4 in skeletal muscle: effects of diabetes and fasting. J Biol Chem 1993;268:13824–13829.
160. Begum N, Draznin B. Effect of streptozotocin induced diabetes on GLUT4 phosphorylation in adipocytes. J Clin Invest 1992;90:1254–1262.
161. Giorgino F, Chen J, Smith RJ. Changes in tyrosine phosphorylation of insulin receptors and a 170,000 molecular weight non receptor protein in vivo in skeletal muscle of streptozotocin induced diabetic rats: effects of insulin and glucose. Endocrinology 1992;130:1433–1444.
162. Penicaud L, Kinde J, LeMagnen L, et al. Insulin action during fasting and refeeding in the rat as determined by euglycemic clamp. Am J Physiol 1985;249:E514–E518.
163. Charron MJ, Kahn BB. Divergent molecular mechanisms for insulin resistant glucose transport in muscle and adipose cells in vivo. J Biol Chem 1990;265:7994–8000.
164. Kahn BB, Rosen AS. Increased insulin stimulated recruitment of GLUT4 to the plasma membrane in skeletal muscle of fasted rats. Diabetes 1992;41(suppl):12A.
165. Smith D, Bloom S, Sugden M, et al. Glucose transporter expression and glucose utilization in skeletal muscle and brown adipose tissue during starvation and refeeding. Biochem J 1992;282:231–235.
166. Liu ML, Olson AL, Moye-Rowley WS, et al. Expression and regulation of the human GLUT4/muscle-fat facilitative glucose transporter gene in transgenic mice. J Biol Chem 1992;267:11673–11676.
167. Olson AL, Liu ML, Moye-Rowley WS, et al. Hormonal/metabolic regulation of the human GLUT4/muscle-fat facilitative glucose transporter gene in transgenic mice. J Biol Chem 1993;268:9839–9846.
168. Thai MV, Guruswamy S, Cao KT, et al. Myocyte enhancer factor 2 (MEF2)-binding site is required for GLUT4 gene expression in transgenic mice: regulation of MEF2 DNA binding activity in insulin-deficient diabetes. J Biol Chem 1998;273:14285–14292.
169. MacLean PS, Zheng D, Jones JP, et al. Exercise-induced transcription of the muscle glucose transporter (GLUT 4) gene. Biochem Biophys Res Commun 2002;292:409–414.
170. Gray S, Feinberg MW, Hull S, et al. The Kruppel-like factor KLF15 regulates the insulin-sensitive glucose transporter GLUT4. J Biol Chem 2002;277:34322–34328.
171. Liu ML, Gibbs EM, McCoid SC, et al. Transgenic mice overexpressing the human GLUT4 muscle fat facilitative glucose transporter protein exhibit efficient glycemic control. Proc Natl Acad Sci USA 1993;90:11346–11350.
172. Treadway JL, Hargrove DM, Nardone NA, et al. Enhanced peripheral glucose utilization in transgenic mice expressing the human GLUT4 gene. J Biol Chem 1994;269:29956–29961.
173. Ren JM, Marshall BA, Mueckler MM, et al. Overexpression of GLUT4 protein in muscle increases basal and insulin stimulated whole body glucose disposal in conscious mice. J Clin Invest 1995; 95:429–432.
174. Leturque A, Loizeau M, Vaulont S, et al. Improvement in insulin action in diabetic transgenic mice selectively overexpressing GLUT4 in skeletal muscle. Diabetes 1996;45:23–27.
175. Tsao T, Stenbit AE, Factor SM, et al. Prevention of insulin resistance and diabetes in mice heterozygous for GLUT4 ablation by transgenic complementation of GLUT4 in skeletal muscle. Diabetes 1999;48:775–782.
176. Shepherd PR, Gnudi L, Tozzo E, et al. Adipose cell hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in adipose tissue. J Biol Chem 1993;268:22243–22246.
177. Tozzo E, Shepherd PR, Gnudi L, et al. Transgenic Glut 4 overexpression in fat enhances glucose metabolism: preferential effect on fatty acid synthesis. Am J Physiol 1995;268:E956–E964.
178. Gnudi L, Tozzo E, Shepherd PR, et al. High level overexpression of glucose transporter 4 driven by an adipose specific promoter is maintained in transgenic mice on a high fat diet but does not prevent impaired glucose tolerance. Endocrinology 1995;136:995–1002.
179. Gibbs EM, Stock JL, McCoid SC, et al. Glycemic improvement in diabetic db/db mice by overexpression of the human insulin regulatable glucose transporter GLUT4. J Clin Invest 1995;95:1512–1518.
180. Ikemoto S, Thompson KS, Takahashi M, et al. High fat diet induced hyperglycemia: prevention by low level expression of a glucose transporter minigene in transgenic mice. Proc Natl Acad Sci USA 1995;92:3096–3099.
181. Tozzo E, Gnudi L, Kahn BB. Amelioration of insulin resistance in streptozotocin diabetic mice by transgenic overexpression of GLUT4 driven by an adipose specific promoter. Endocrinology 1997;138: 1604–1611.
182. Hebert LF, Daniels MC, Zhou J, et al. Overexpression of glutamine: fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance. J Clin Invest 1996;98:930–936.
183. Valera A, Pujol A, Pelegrin M, et al. Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop NIDDM. Proc Natl Acad Sci USA 1994;91:9151–9154.
184. Cooksey RC, Hebert LF Jr, Zhu JH, et al. Mechanism of hexosamine-induced insulin resistance in transgenic mice overexpressing glutamine:fructose-6-phosphate amidotransferase: decreased glucose transporter GLUT4 translocation and reversal by treatment with thiazolidinedione. Endocrinology 1999;140:1151–1157.
185. Katz EB, Stenbit AE, Hatton K, et al. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature 1995;377:151–155.
186. Abel ED, Kaulbach HC, Tian R, et al. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J Clin Invest 1999;104:1703–1714.
187. Minokoshi Y, Kahn CR, Kahn BB. Tissue-specific ablation of the GLUT4 glucose transporter or the insulin receptor challenges assumptions about insulin action and glucose homeostasis. J Biol Chem 2003;278:33609–33612.
188. Stenbit AE, Tsao T, Li J, et al. GLUT4 heterozygous knockout mice develop muscle insulin resistance and diabetes. Nat Med 1997;3: 1096–1101.
189. Zisman A, Peroni OD, Abel ED, et al. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat Med 2000;6:924–928.
190. Kim JK, Zisman A, Fillmore JJ, et al. Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4. J Clin Invest 2001;108:153–160.
191. Marshall BA, Ren JM, Johnson DW, et al. Germline manipulation of glucose homeostasis via alteration of glucose transporter levels in skeletal muscle. J Biol Chem 1993;268:18442–18445.
192. Gulve EA, Ren JM, Marshall BA, et al. Glucose transport activity in skeletal muscles from transgenic mice overexpressing GLUT1: increased basal transport is associated with a defective response to diverse stimuli that activate GLUT4. J Biol Chem 1994;269:18366–18370.
193. Hansen PA, Wang W, Marshall BA, et al. Dissociation of GLUT4 translocation and insulin-stimulated glucose transport in transgenic mice overexpressing GLUT1 in skeletal muscle. J Biol Chem 1998; 273:18173–18179.
194. Keller SR, Davis AC, Clairmont KB. Mice deficient in the insulin-regulated membrane aminopeptidase show substantial decreases in glucose transporter GLUT4 levels but maintain normal glucose homeostasis. J Biol Chem 2002;277:17677–17686.
195. Yang C, Coker KJ, Kim JK, et al. Syntaxin 4 heterozygous knockout mice develop muscle insulin resistance. J Clin Invest 2001;107: 1311–1318.
196. Lund S, Holman GD, Schmitz O, et al. Contraction stimulates translocation of glucose transporter Glut4 in skeletal muscle through a mechanism distinct from that of insulin. Proc Natl Acad Sci USA 1995;92:5817–5821.
197. Brozinick J, Etgen GJ, Yaspelkis BB, et al. The effects of muscle contraction and insulin on glucose transporter translocation in skeletal muscle. Biochem J 1994;297:539.
198. Goodyear LJ, Hirshman MF, Valyou PM, et al. Glucose transporter number, function, and subcellular distribution in rat skeletal muscle after exercise training. Diabetes 1992;41:1091–1099.
199. Brozinick JJ, Etgen G, Yaspelkis BB, et al. Effects of exercise training on GLUT4 protein content and translocation in obese Zucker rats. Am J Physiol 1993;265:E419–E427.
200. Kern M, Dolan PL, Mazzeo RS, et al. Effect of aging and exercise on GLUT-4 glucose transporters in muscle. Am J Physiol 1992;263: E362–E367.
201. Hughes VA, Fiatarone MA, Fielding RA, et al. Exercise increases muscle GLUT4 levels and insulin action in subjects with glucose intolerance. Am J Physiol 1993;264:E855–E862.
202. Etgen GJ, Brozinick GJ, Hy K, et al. Effects of exercise training on skeletal muscle glucose uptake and transport. Am J Physiol 1993; 264:C727–C733.
203. Ren JM, Semenkovich CF, Gulve EA, et al. Exercise induces rapid increases in GLUT4 expression, glucose transport capacity, and insulin-stimulated glycogen storage in muscle. J Biol Chem 1994; 269:14396–14401.
204. Henriksen EJ, Rodnick KJ, Mondon CE, et al. Effect of denervation or unweighting on GLUT4 protein in rat soleus muscle. J Appl Physiol 1991;70:2322–2327.
205. Fryer LG, Foufelle F, Barnes K, et al. Characterization of the role of the AMP-activated protein kinase in the stimulation of glucose transport in skeletal muscle cells. Biochem J 2002;363:167–174.
206. Ploug T, Ohkuwa T, Handberg A, et al. Effect of immobilization of glucose transport and glucose transporter expression in rat skeletal muscle. Am J Physiol 1995;268:E980–E986.
207. Fushiki T, Kano T, Inoue K, et al. Decrease in muscle glucose transporter number in chronic physical inactivity. Am J Physiol 1991;260: E403–E410.
208. Han XX, Fernando PK, Bonen A. Denervation provokes greater reductions in insulin-stimulated glucose transport in muscle than severe diabetes. Mol Cell Biochem 2000;210:81–89.
209. Wilkes JJ, Bonen A. Reduced insulin-stimulated glucose transport in denervated muscle is associated with impaired Akt-alpha activation. Am J Physiol Endocrinol Metab 2000;279:E912–E919.
210. Burant CF, Treutelaar MK, Buse MG. In vitro and in vivo activation of the insulin receptor tyrosine kinase in control and denervated skeletal muscle. J Biol Chem 1986;261:8985–8993.
211. Etgen GJ, Farrar R, Ivy J. Effect of chronic electrical stimulation on GLUT4 protein content in fast twitch muscle. Am J Physiol 1993; 264:R816–R819.
212. Megeney LA, Michel RN, Boudreau CS, et al. Regulation of muscle glucose transport and GLUT4 by nerve derived factors and activity related processes. Am J Physiol 1995;269:R1148–R1153.
213. Suarez E, Bach D, Cadefau J, et al. A novel role of neuregulin in skeletal muscle: neuregulin stimulates glucose uptake, glucose transporter translocation, and transporter expression in muscle cells. J Biol Chem 2001;276:18257–18264.
214. Hjeltnes N, Galuska D, Bjornholm M, et al. Exercise induced overexpression of key regulatory proteins involved in glucose uptake and metabolism in tetraplegic persons: molecular mechanism for improved glucose homeostasis. FASEB J 1998;12:1701–1712.
215. Muller G, Wied S. The sulphylurea drug glimepiride stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin resistant rat adipocytes in vitro. Diabetes 1993;42: 1852–1867.
216. Kozka I, Holman G. Metformin blocks downregulation of cell surface GLUT4 caused by chronic insulin treatment of rat adipocytes. Diabetes 1993;42:1159–1165.
217. Matthaei S, Reibold J, Hamann A, et al. In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin induced translocation and increased functional activity of glucose transporters in obese Zucker rat adipocytes. Endocrinology 1993;133:304–311.
218. Handberg A, Kayser L, Hoyer P, et al. Metformin ameliorates diabetes but does not normalize decreased GLUT4 content in skeletal muscle of obese Zucker rats. Diabetologia 1993;36:481–486.
219. Hundal H, Ramlal T, Reyes R, et al. Cellular mechanism of metformin action involves glucose transporter translocation from intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology 1992;131:1165–1173.
220. Galuska D, Nolte LA, Zierath JR, et al. Effect of metformin on insulin stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM. Diabetologia 1994;37:826–832.
221. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167–1174.
222. Hawley SA, Gadalla AE, Olsen GS, et al. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 2002;51: 2420–2425.
223. Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002;51:2074–2081.
224. Kim YB, Ciaraldi TP, Kong A, et al. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes 2002;51:443–448.
225. Hulin B, McCarthy PA, Gibbs EM. The glitazone family of antidiabetic agents. Curr Pharmaceutical Design 1996;2:85–102.
226. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661–1669.
227. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type-2 diabetes mellitus. N Engl J Med 1998;338:867–872.
228. Young PW, Cawthorne MA, Coyle PJ, et al. Repeat treatment of obese mice with BRL49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes: association with increased insulin binding and cell surface GLUT4 as measured by photoaffinity labeling. Diabetes 1995;44:1087–1092.
229. Szalkowski D, White-Carrington S, Berger J, et al. Antidiabetic thiazolidinediones block the inhibitory effect of tumour necrosis factor alpha on differentiation, insulin stimulated glucose uptake and gene expression in 3T3-L1 cells. Endocrinology 1995;136: 1474–1481.
230. Oakes ND, Kennedy CJ, Jenkins AB, et al. A new antidiabetic agent, BRL-49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 1994;43:1203–1210.
231. Jucker BM, Schaeffer TR, Haimbach RE, et al. Normalization of skeletal muscle glycogen synthesis and glycolysis in rosiglitazone-treated Zucker fatty rats: an in vivo nuclear magnetic resonance study. Diabetes 2002;51:2066–2073.
232. Petersen KF, Krssak M, Inzucchi S, et al. Mechanism of troglitazone action in type 2 diabetes. Diabetes 2000;49:827–831.
233. Ciaraldi TP, Kong AP, Chu NV, et al. Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes 2002;51:30–36.
234. Shintani M, Nishimura H, Yonemitsu S, et al. Troglitazone not only increases GLUT4 but also induces its translocation in rat adipocytes. Diabetes 2001;50:2296–2300.
235. Yonemitsu S, Nishimura H, Shintani M, et al. Troglitazone induces GLUT4 translocation in L6 myotubes. Diabetes 2001;50:1093–1101.
236. Fryer LG, Parbu-Patel A, Carling D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002;277:25226–25232.
237. Maier VH, Melvin DR, Lister CA, et al. v- and t-SNARE protein expression in models of insulin resistance: normalization of glycemia by rosiglitazone treatment corrects overexpression of cellubrevin, vesicle-associated membrane protein-2, and syntaxin 4 in skeletal muscle of Zucker diabetic fatty rats. Diabetes 2000;49:618–625.
238. Hirshman MF, Fagnant PM, Horton ED, et al. Pioglitazone treatment for 7 days failed to correct the defect in glucose transport and glucose transporter translocation in obese Zucker rat (fa/fa) skeletal muscle. Biochem Biophys Res Commun 1995;208:835–845.
239. Ciaraldi T, Henry RR. Thiazolidinediones and their effects on glucose transport. Eur J Endocrinol 1997;137:610–612.
240. Brichard SM, Henquin JC. The role of vanadium in the management of diabetes. Trends Pharmacol Sci 1995;16:265–270.
241. Paquet MR, Romanek RJ, Sargent RJ. Vanadate induces the recruitment of GLUT4 glucose transporter to the plasma membrane of rat adipocytes. Mol Cell Biochem 1992;109:149–155.
242. Castello A, Rodriguez-Manzaneque J, Camps M, et al. Perinatal hypothyroidism impairs normal transition from GLUT1 to GLUT4 from fetal to neonatal levels in heart and brown adipose tissue. J Biol Chem 1994;269:5905.
243. Weinstein SP, O’Boyle E, Haber RS. Thyroid hormone increases basal and insulin stimulated glucose transport in skeletal muscle: role of GLUT4 glucose transporter expression. Diabetes 1994;43:1185–1189.
244. Weinstein SP, Watts J, Haber RS. Thyroid hormone increases muscle/fat glucose transporter gene expression in rat skeletal muscle. Endocrinology 1991;129:455–464.
245. Casla A, Rovira A, Wells JA, et al. Increased glucose transporter (GLUT4) protein expression in hyperthyroidism. Biochem Biophys Res Commun 1990;171:182–188.
246. Romero R, Casanova B, Pulido N, et al. Stimulation of glucose transport by thyroid hormone in 3T3-L1 adipocytes: increased abundance of GLUT1 and GLUT4 glucose transporter proteins. J Endocrinol 2000;164:187–195.
247. Weinstein SP, Haber RS. Differential regulation of glucose transporter isoforms by thyroid hormone in rat heart. Biochim Biophys Acta 1992;1136:302–308.
248. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145–153.
249. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321:868–873.
250. Henriksen EJ, Jacob S, Kinnick TR, et al. ACE inhibition and glucose transport in insulin-resistant muscle: roles of bradykinin and nitric oxide. Am J Physiol 1999;277:R332–R336.
251. Velloso LA, Folli F, Sun XJ, et al. Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 1996;93: 12490–12495.
252. Shiuchi T, Cui TX, Wu L, et al. ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 2002;40:329–334.
253. Henriksen EJ, Jacob S, Kinnick TR, et al. Selective angiotensin II receptor receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 2001;38:884–890.
254. Hoenack C, Roesen P. Inhibition of angiotensin type 1 receptor prevents decline of glucose transporter (GLUT4) in diabetic rat heart. Diabetes 1996;45(suppl 1):82–87.
255. Ishizawa K, Yoshizumi M, Tsuchiya K, et al. Effects of losartan in combination with or without exercise on insulin resistance in Otsuka Long-Evans Tokushima Fatty rats. Eur J Pharmacol 2001;430:359–367.
256. Foianini KR, Steen MS, Kinnick TR, et al. Effects of exercise training and ACE inhibition on insulin action in rat skeletal muscle. J Appl Physiol 2000;89:687–694.
257. Wu-Wong JR, Berg CE, Kramer D. Endothelin stimulates glucose uptake via activation of endothelin-A receptor in neonatal rat cardiomyocytes. J Cardiovasc Pharmacol 2000;36(suppl):179–183.
258. Imamura T, Ishibashi K, Dalle S, et al. Endothelin-1-induced GLUT4 translocation is mediated via Galpha(q/11) protein and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. J Biol Chem 1999;274:33691–33695.
259. Wu-Wong JR, Berg CE, Wang J, et al. Endothelin stimulates glucose uptake and GLUT4 translocation via activation of endothelin ETA receptor in 3T3-L1 adipocytes. J Biol Chem 1999;274:8103–8110.
260. Ishibashi K, Imamura T, Sharma PM, et al. The acute and chronic stimulatory effects of endothelin-1 on glucose transport are mediated by distinct pathways in 3T3-L1 adipocytes. Endocrinology 2000;141:4623–4628.
261. Park JG, Bose A, Leszyk J, et al. PYK2 as a mediator of endothelin-1/G alpha 11 signaling to GLUT4 glucose transporters. J Biol Chem 2001;276:47751–47754.
262. Bose A, Cherniack AD, Langille SE, et al. G(alpha)11 signaling through ARF6 regulates F-actin mobilization and GLUT4 glucose transporter translocation to the plasma membrane. Mol Cell Biol 2001;21:5262–5275.
263. Lawrence JT, Birnbaum MJ. Adp-ribosylation factor 6 delineates separate pathways used by endothelin 1 and insulin for stimulating glucose uptake in 3T3-L1 adipocytes. Mol Cell Biol 2001;21:5276–5285.
264. Ishibashi KI, Imamura T, Sharma PM, et al. Chronic endothelin-1 treatment leads to heterologous desensitization of insulin signaling in 3T3-L1 adipocytes. J Clin Invest 2001;107:1193–1202.
265. Sarman B, Toth M, Somogyi A. Role of endothelin-1 in diabetes mellitus. Diabetes Metab Rev 1998;14:171–175.
266. Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002;16:F1–F8.
267. Hruz PW, Murata H, Qiu H, et al. Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes 2002;51: 937–942.
268. Nolte LA, Yarasheski KE, Kawanaka K, et al. The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle. Diabetes 2001;50:1397–1401.
269. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275:20251–20254.
270. Murata H, Hruz PW, Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 2002;16:859–863.
271. Hruz PW, Murata H, Mueckler M. Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism. Am J Physiol Endocrinol Metab 2001;280:E549–E553.
272. Shimizu Y, Nikami H, Tsukazaki K, et al. Importance of sympathetic nerves for the stimulatory effects of cold exposure on glucose utilization in brown adipose tissue. Am J Physiol 1993;264:E890–E895.
273. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor a: direct role in obesity linked insulin resistance. Science 1993;259:87–91.
274. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992;130:43–52.
275. Stephens JM. Transcriptional repression of the C/EBP-a and GLUT4 genes in 3T3-L1 adipocytes by tumour necrosis factor-α. J Biol Chem 1992;267:13580–13584.
276. Hauner H, Petruschke T, Russ M, et al. Effects of tumour necrosis factor alpha on glucose transport and lipid metabolism on newly differentiated fat cells in culture. Diabetologia 1995;38:764–771.
277. Stephens JM, Lee J, Pilch PF. Tumour necrosis factor alpha induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate 1 and GLUT4 without a loss of insulin mediated signal transduction. J Biol Chem 1997;272:971–976.
278. Furnsinn C, Neschen S, Wagner O, et al. Acute and chronic exposure to tumour necrosis factor alpha fails to affect insulin stimulated glucose metabolism in isolated rat soleus muscle. Endocrinology 1997;138:2674–2679.
279. Nolte LA, Rincon J, Odegaard-Wahlstrom E, et al. Hyperglycemia activates glucose transport in rat skeletal muscle via a Ca2+ dependent mechanism. Diabetes 1995;44:1345–1348.
280. Ciaraldi TP, Carter L, Mudaliar S, et al. Effects of tumour necrosis factor alpha on glucose metabolism in cultured human muscle cells from non diabetic and type2 diabetic subjects. Endocrinology 1998; 139:4793–4800.
281. Schreyer SA, Chua SC, LeBouef RC. Obesity and diabetes in TNF-α receptor deficient mice. J Clin Invest 1998;102:402–411.
282. Uysal KT, Wiesbrock SM, Marino MW, et al. Protection from obesity induced insulin resistance in mice lacking TNF-α function. Nature 1997;389:610–614.
283. Ventre J, Doebber T, Wu M, et al. Targeted disruption of the tumor necrosis factor-α gene: metabolic consequences in obese and non-obese mice. Diabetes 1997;46:1526–1531.
284. Ofei F, Hurel S, Newkirk J, et al. Effects of an engineered human anti-TNFalpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996;45:881–885.
285. Bray GA, York DA. Leptin and clinical medicine: a new piece in the puzzle of obesity. J Clin Endocrinol Metab 1997;82:2771–2776.
286. Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight reduced subjects. Nat Med 1995;1:1155–1161.
287. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive leptin levels in normal weight and obese humans. N Engl J Med 1996;334:292–295.
288. Sivitz WI, Walsh SA, Morgan DA, et al. Effects of leptin on insulin sensitivity in normal rats. Endocrinology 1997;138:3395–3401.
289. Kamohara S, Burcelin R, Halaas JL, et al. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 1997;389:374–377.
290. Berti L, Kellerer M, Capp E, et al. Leptin stimulates glucose transport and glycogen synthesis in C2C12 myotubes: evidence for a PI 3-kinase mediated effect. Diabetologia 1997;40:606–609.
291. Muller G, Ertl J, Gerl M, et al. Leptin impairs the metabolic actions of insulin in isolated rat adipocytes. J Biol Chem 1997;272:10585–10593.
292. Sweeney G, Keen J, Somwar R, et al. High leptin levels acutely inhibit insulin-stimulated glucose uptake without affecting glucose transporter 4 translocation in L6 rat skeletal muscle cells. Endocrinology 2001;142:4806–4812.
293. Muoio DM, Dohm GL, Fiedorek FT, et al. Leptin directly alters lipid partitioning in skeletal muscle. Diabetes 1997;46:1360–1363.
294. Ranganathan S, Ciaraldi TP, Henry RR, et al. Lack of effect of leptin on glucose transport, lipoprotein lipase and insulin action in adipose and muscle cells. Endocrinology 1998;139:2509–2513.
295. Zierath JR, Frevert EU, Ryder JW, et al. Evidence against a direct effect of leptin on glucose transport in skeletal muscle and adipocytes. Diabetes 1997;47:1–4.
296. Furnsinn C, Brunmair B, Furtmuller R, et al. Failure of leptin to affect basal and insulin stimulated glucose metabolism in rat skeletal muscle in vitro. Diabetologia 1998;41:524–529.
297. LiSen L, Karkanias GB, Morales JC, et al. Intracerebroventricular leptin regulates hepatic but not periperal glucose fluxes. J Biol Chem 1998;273:31160–31167.
298. Shepherd PR, Crowther N, Desai M, et al. Altered adipocyte properties in the offspring of protein malnourished rats. Br J Nutr 1997; 78:121–129.
299. Ozanne SE, Wang CL, Coleman N, et al. Altered muscle insulin sensitivity in the male offspring of protein-malnourished rats. Am J Physiol 1996;271:E1128–E1134.
300. Jaquet D, Vidal H, Hankard R, et al. Impaired regulation of glucose transporter 4 gene expression in insulin resistance associated with in utero undernutrition. J Clin Endocrinol Metab 2001;86:3266–3271.